Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Republic of Korea.
Graefes Arch Clin Exp Ophthalmol. 2013 Feb;251(2):501-8. doi: 10.1007/s00417-012-2067-8. Epub 2012 Jun 1.
To evaluate the baseline spectral-domain optical coherence tomography (SD-OCT) characteristics of macular edema (ME) due to branch retinal vein occlusion (BRVO) for visual outcome after intravitreal bevacizumab injection.
Fifty-nine patients treated in one eye with intravitreal bevacizumab for ME due to BRVO were retrospectively reviewed. Stepwise multiple regression analysis was used to evaluate the relative contribution of several variables, including SD-OCT characteristics such as photoreceptor inner segment/outer segment (IS/OS) integrity and external limiting membrane (ELM status), baseline best-corrected visual acuity (BCVA), and baseline central retinal thickness (CRT) with final visual outcome.
Thirty-one patients (52.5 %) had disrupted photoreceptor IS/OS integrity. The mean BCVA improved significantly from 0.50 logMAR (20/63 Snellen equivalent) to 0.10 logMAR (20/25 Snellen equivalent) in the intact photoreceptor group (p = 0.000, paired t-test). However, the mean BCVA was improved in the disrupted photoreceptor group, from 1.10 logMAR (20/252 Snellen equivalent) to 0.94 logMAR (20/174 Snellen equivalent), which was not statistically significant (p = 0.177, paired t-test). ELM was disrupted in 23 patients (39.0 %). The mean BCVA improved significantly from 0.63 logMAR (20/85 Snellen equivalent) to 0.26 logMAR (20/36 Snellen equivalent) in the intact ELM group (p = 0.000, paired t-test), however, not significantly improved in the disrupted ELM group, from 1.09 logMAR (20/246 Snellen equivalent) to 1.01 logMAR (20/205 Snellen equivalent) (p = 0.563, paired t-test). The strongest individual predictor of final BCVA among patients with ME due to BRVO was the integrity of photoreceptor IS/OS layer on SD OCT (r (2) = 0.514, p = 0.000, stepwise multiple regression), but the most efficient model was the combination of the photoreceptor IS/OS integrity, ELM status, and baseline BCVA (r(2) = 0.671, p = 0.000, stepwise multiple regression). The strongest predictor of final BCVA was the status of photoreceptor IS/OS integrity (β = 0.532, p = 0.000, stepwise multiple regression), followed by ELM status (β = 0.325, p = 0.006, stepwise multiple regression), and the baseline BCVA (β = 0.238, p = 0.013, stepwise multiple regression).
Our results suggest that baseline SD-OCT characteristics, the status of photoreceptor IS/OS and ELM can be helpful in predicting the final visual outcome after intravitreal bevacizumab injection in these patients.
评估分支静脉阻塞(BRVO)引起的黄斑水肿(ME)的基线频域光相干断层扫描(SD-OCT)特征,以预测玻璃体内注射贝伐单抗后的视力结果。
回顾性分析 59 例 BRVO 引起的 ME 患者,对其中 1 只眼进行玻璃体内注射贝伐单抗治疗。采用逐步多元回归分析,评估 SD-OCT 特征(如光感受器内节/外节(IS/OS)完整性和外界膜(ELM)状态)、基线最佳矫正视力(BCVA)和基线中心视网膜厚度(CRT)与最终视力结果的相对贡献。
31 例(52.5%)患者的光感受器 IS/OS 完整性受损。在完整光感受器组,BCVA 从 0.50 logMAR(20/63 视力表等效)显著改善至 0.10 logMAR(20/25 视力表等效)(p=0.000,配对 t 检验)。然而,在光感受器受损组,BCVA 从 1.10 logMAR(20/252 视力表等效)改善至 0.94 logMAR(20/174 视力表等效),但无统计学意义(p=0.177,配对 t 检验)。23 例(39.0%)ELM 受损。在完整 ELM 组,BCVA 从 0.63 logMAR(20/85 视力表等效)显著改善至 0.26 logMAR(20/36 视力表等效)(p=0.000,配对 t 检验),而在 ELM 受损组,BCVA 无明显改善,从 1.09 logMAR(20/246 视力表等效)改善至 1.01 logMAR(20/205 视力表等效)(p=0.563,配对 t 检验)。BRVO 引起的 ME 患者中,最终 BCVA 的最强个体预测因子是 SD-OCT 上光感受器 IS/OS 层的完整性(r²=0.514,p=0.000,逐步多元回归),但最有效的模型是光感受器 IS/OS 完整性、ELM 状态和基线 BCVA 的组合(r²=0.671,p=0.000,逐步多元回归)。最终 BCVA 的最强预测因子是光感受器 IS/OS 完整性的状态(β=0.532,p=0.000,逐步多元回归),其次是 ELM 状态(β=0.325,p=0.006,逐步多元回归)和基线 BCVA(β=0.238,p=0.013,逐步多元回归)。
我们的结果表明,基线 SD-OCT 特征、光感受器 IS/OS 和 ELM 的状态有助于预测这些患者玻璃体内注射贝伐单抗后的最终视力结果。